1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 5: Section 10.3.9.

Slides:



Advertisements
Similar presentations
Case Study: Dopamine D 3 Receptor Anthagonists Chapter 3 – Molecular Modeling 1.
Advertisements

NUCLEIC ACIDS AS DRUG TARGETS
Improving Gleevec: Insight from the Receptor Structure Gleevec cannot bind to the open (active) form of the Abl kinase - would collide with open conformation.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 7: Section 10.4.
CHAPTER 10 Basic Biopharmaceutics
Chapter 24 OPIOID RECEPTORS.
Prentice-Hall © 2007 General Chemistry: Chapter 16 Slide 1 of 52  Worked Examples Follow:
7/6/2015 Orthogonal Functions Chapter /6/2015 Orthogonal Functions Chapter 7 2.
Drugs on the Brain Emma Robinson RCUK Academic Fellow.
Drug Design Optimizing Target Interactions
Principles of Pharmacology
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 14 COMBINATORIAL CHEMISTRY Part 2: Sections 14.5 – 14.6.
DESIGN OF A NOVEL ANXIOLYTIC AND ANTIDEPRESSANT AGENT
Drug Discovery & Development
Chapter 8. M M E R Agonists are drugs designed to mimic the natural messenger Agonists should bind and leave quickly - number of binding interactions.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 4: (Lead compounds - Impact of the human genome project)
Pharmacology Ch. 4 Pharmacy Tech. Ch  A receptor (the “Key”) interacts with a drug because it fits the structure of the receptor.  Once the.
 Receptors are mostly membrane-bound proteins that selectively bind small molecules called ligands which results in physiological response.  They are.
Chapter 4 1 © 2011 Pearson Education, Inc. 4.5 Isomerism in Organic Compounds, Part 1 Structural Isomers Structural isomers are compounds with the same.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 19 CHOLINERGICS, ANTICHOLINERGICS & ANTICHOLINESTERASES Part 1: Cholinergics & anticholinesterases.
Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 2: Section 10.2.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 1: Section 10.1 (SAR)
Pharmacophores Chapter 13 Part 2.
Synaptic Transmission How a neuron communicates with another neuron and the effects of drugs on this process. Types of Neurotransmitters.
Rationale : Endogenous lead compounds often simple and flexible (e.g. adrenaline)Endogenous lead compounds often simple and flexible (e.g. adrenaline)
1 © 2. Structure Activity Relationships (SAR) Alter, remove or mask a functional groupAlter, remove or mask a functional group Test the analogue for activityTest.
Several methods are presently used to study SAR.
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Naming Compounds.. 1.Find the parent chain (the longest section of carbons). If the chain is a ring place “cyclo” before the name of the carbon chain.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 1: Sections
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 6: Section
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Patrick: An Introduction to Medicinal Chemistry 5e
An Introduction to Medicinal Chemistry 3/e COMBINATORIAL CHEMISTRY
DRUG DISCOVERY: FINDING A LEAD
NUCLEIC ACIDS AS DRUG TARGETS
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Isomers & Functional Groups
An Introduction to Medicinal Chemistry 3/e
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
CH 4-4: Newman Projections How to draw a Newman Projection for butane
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
CHOLINERGICS, ANTICHOLINERGICS & ANTICHOLINESTERASES
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Chapter 1: Introduction
How Medicines Work: Stimulation and Inhibition
Advanced Higher Chemistry Unit 3(e)
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Receptors & Drug action at Receptors
Amino Acids An amino acid is any compound that contains an amino group (—NH2) and a carboxyl group (—COOH) in the same molecule.
Patrick: An Introduction to Medicinal Chemistry 6e
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Hormones Biology 12.
ORGANIC PHARMACEUTICAL CHEMISTRY IV
Biopharmaceutics Pharmacy Technician.
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Patrick: An Introduction to Medicinal Chemistry 5e ANTICANCER AGENTS
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Sachin Shinde Department of Chemistry S.M.Joshi College Hadapsar
Targets for drug action
Patrick: An Introduction to Medicinal Chemistry 6e
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Presentation transcript:

1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 5: Section

1 © Contents 4.9.Rigidification -Methods - Introduce rings (2 slides) -Methods - Introduce rigid functional groups -Examples -Examples - Combretastatin (anticancer agent) -Methods - Steric Blockers -Steric Blockers – Examples (2 slides)

1 © Rationale : Endogenous lead compounds often simple and flexible (e.g. adrenaline)Endogenous lead compounds often simple and flexible (e.g. adrenaline) Fit several targets due to different active conformations (e.g. adrenergic receptor types and subtypes)Fit several targets due to different active conformations (e.g. adrenergic receptor types and subtypes) 4.9 Rigidification Rigidify molecule to limit conformations - conformational restraintRigidify molecule to limit conformations - conformational restraint Increases activity (more chance of desired active conformation)Increases activity (more chance of desired active conformation) Increases selectivity (less chance of undesired active conformations )Increases selectivity (less chance of undesired active conformations )Disadvantage: Molecule more complex and may be more difficultMolecule more complex and may be more difficult to synthesise

1 © 4.9 Rigidification RECEPTOR 1 RECEPTOR 2

1 © Methods - Introduce rings Bonds within ring systems are locked and cannot rotate freely 4.9 Rigidification

1 © Methods - Introduce rings Bonds within ring systems are locked and cannot rotate freely 4.9 Rigidification Test rigid structures to see which ones have retained active conformation

1 © Methods - Introduce rigid functional groups 4.9 Rigidification

1 © Important binding groups Rigid Rigid Rigid Examples 4.9 Rigidification Inhibits platelet aggregationAnalogues

1 © Examples - Combretastatin (anticancer agent) 4.9 Rigidification More active Less activeRotatablebond

1 © Methods - Steric Blockers 4.9 Rigidification Flexible side chain Coplanarity allowed Orthogonal rings preferred Introduce steric block Introduce steric block

1 © Steric clash Steric Blockers - Examples 4.9 Rigidification Increase in activity Active conformation retained Serotonin antagonist Introduce methyl group

1 © Steric clash Steric Blockers - Examples 4.9 Rigidification D 3 AntagonistInactive Active conformation disallowed